Initial Management of Overactive Bladder in Elderly Men
Clinical Decision Algorithm
- The American Urological Association recommends starting with mirabegron 25 mg once daily as the first-line pharmacologic agent for an elderly man with overactive bladder, particularly if he is frail or has multiple comorbidities, due to its comparable efficacy to antimuscarinics with a more favorable side effect profile 1, 2
- Before initiating any OAB medication in an elderly man, it is essential to assess for bladder outlet obstruction (BOO) by checking post-void residual (PVR) volume to avoid precipitating urinary retention 3
- The European Association of Urology suggests performing urine flow studies if available to assess for obstruction, and if BOO is present (Qmax <10 mL/sec), α-blockers become first-line, not antimuscarinic or β3-agonist monotherapy 4, 5
Special Considerations
- The American Urological Association notes that β3-adrenoceptor agonists have an efficacy profile similar to anti-muscarinics and a relatively lower adverse event profile, making them a suitable option for elderly men 6
- For patients with coexisting BOO and OAB symptoms, combination α-blocker + antimuscarinic therapy has increasing evidence of safety and efficacy, but it is recommended to start the α-blocker first, ensure adequate voiding, then add OAB medication 4, 5
- The International Continence Society defines treatment failure as a patient who has failed behavioral therapy of 8-12 weeks duration and at least one medication trial for 4-8 weeks, at which point referral to urology for third-line therapies is recommended 6
Monitoring and Treatment Adjustment
- Regular monitoring of blood pressure is necessary, especially during initial treatment with mirabegron, as it can increase blood pressure and heart rate 1
- The European Association of Urology recommends reassessing patients at 4-8 weeks to evaluate symptom improvement and tolerability, and considering increasing the dose to 50 mg daily if inadequate response and patient tolerates 25 mg well 1, 5